About
22.46USD+0.26 +1.17%
Closed • Updated at 21:37 GMT+00:00Market Cap$1.66B
P/E Ratio3.73
Volume1.19M
Beta-0.02
RSI46.57
Gross Margin71.36%
Innoviva, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 6 2026
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Mar 10 2026
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Feb 25 2026
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Feb 19 2026
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Dec 12 2025
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
Community Chat
Ask AI
Try asking
Translate